Aseptic Meningitis Syndrome With Immunoglobulin Therapy

Amy E. Clarke, DNP, RN, IgCN®Chief Clinical OfficerImmunoglobulin National SocietyCalabasas, CaliforniaLuba Sobolevsky, PharmD, IgCP®President and CEOImmunoglobulin National SocietyCalabasas, CaliforniaAseptic meningitis syndrome (AMS) is a recognized but relatively rare adverse event associated with intravenous immunoglobulin (IVIG) therapy and less commonly with subcutaneous immunoglobulin (SCIG) therapy.1,2Although rare, AMS occurs in approximately 0.6% to 1% of patients receiving IVI